Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience

Fig. 1

Flow diagram to identify patients with PB-DHL. PB-DHL primary breast double-hit lymphoma, R-HyperCVAD rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with cytarabine plus methotrexate, DA-EPOCH-R rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, DA-EPOCH-R/MA rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, alternating with high-dose methotrexate and cytarabine

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us